Bots, editor, reviewer, Administrators
13,941
edits
Feed:All articles/Pretty: Difference between revisions
Jump to navigation
Jump to search
no edit summary
No edit summary |
No edit summary |
||
| Line 2,846: | Line 2,846: | ||
"title" : "Coronary-Artery Bypass Surgery in Patients with Left Ventricular Dysfunction", | "title" : "Coronary-Artery Bypass Surgery in Patients with Left Ventricular Dysfunction", | ||
"pmid" : "21463150" | "pmid" : "21463150" | ||
}, | |||
{ | |||
"timestamp" : "2014-06-08T00:17:08Z", | |||
"briefDesignDescription" : "R-B vs. R-CHOP for indolent lymphomas", | |||
"fulltexturl" : "http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(12)61763-2", | |||
"pageid" : 1664, | |||
"pdfurl" : "http://bit.ly/1owpykX", | |||
"trainingLevel" : "fellow", | |||
"citation" : "Rummel MJ, <i>et al</i>. \"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial\". <i>The Lancet</i>. 2013. 381(9873):1203-10.", | |||
"subspecialties" : "Oncology;Hematology", | |||
"expansion" : "Study Group Indolent Lymphomas", | |||
"briefResultsDescription" : "R-B superior to R-CHOP in PFS, similar in OS, less toxic", | |||
"published" : "2013-04-03", | |||
"pageName" : "StiL", | |||
"diseases" : "Lymphoma", | |||
"abbreviation" : "StiL", | |||
"title" : "Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial", | |||
"pmid" : "23433739" | |||
}, | }, | ||
{ | { | ||